Skip to content

Study · Ex vivo tissue · rat · 2003

5 results

Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart.

Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R

Basic research in cardiology21 Aug 2003Cited by 73 (Europe PMC)

PMID14556085 (opens in a new tab)DOI10.1007/s00395-003-0434-7 (opens in a new tab)PepBankPUB-14556085
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In isolated working rat hearts under aerobic conditions, hexarelin produced no significant hemodynamic effects.

    In plain wordsIn isolated rat hearts under normal oxygen, hexarelin did not change heart performance.

    Peptide
    Hexarelin
    Outcome
    No significant changeHemodynamic effects under aerobic conditions
    Study

    ratn: not reported in source

    isolated working hearts
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Under aerobic conditions, none of these substances produced any significant hemodynamic effects.
    1 context sentence
    Summary · context
    We have investigated the effect of different growth hormone secretagogues on contractile performance and on the susceptibility to ischemic injury, in isolated working rat hearts.
  2. 02LabEx vivo tissueEfficacy outcome

    In isolated rat hearts subjected to 30 minutes of ischemia and 120 minutes of reperfusion, hexarelin significantly reduced infarct size.

    In plain wordsIn isolated rat hearts, hexarelin reduced the size of the damaged heart area after blocked blood flow.

    Peptide
    Hexarelin
    Outcome
    DecreaseInfarct size after 30 min ischemia and 120 min reperfusion
    Study

    ratn: not reported in source

    isolated working hearts
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1 microMAs given in this study (rat).

    Measurements

    concentration
    1 microM
    hexarelin

    Source sentences

    Summary
    In hearts subjected to 30 minutes of ischemia followed by 120 minutes of reperfusion, the synthetic peptidyl secretagogue hexarelin (1 microM) significantly reduced infarct size, as estimated on the basis of triphenyltetrazolium chloride staining, while the non-peptidyl secretagogue MK-0677 was ineffective.
    1 context sentence
    Summary · context
    We have investigated the effect of different growth hormone secretagogues on contractile performance and on the susceptibility to ischemic injury, in isolated working rat hearts.
  3. 03LabEx vivo tissueMechanism

    In isolated rat hearts, the protein kinase C inhibitor chelerythrine partly abolished the protection provided by hexarelin.

    In plain wordsIn isolated rat hearts, a protein kinase C blocker partly removed the protection that hexarelin gave.

    Peptide
    Hexarelin
    Outcome
    Not applicableProtein kinase C dependence of hexarelin cardioprotection
    Study

    ratn: not reported in source

    isolated working hearts
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The protection provided by hexarelin was partly abolished by the protein kinase C inhibitor chelerythrine.
    1 context sentence
    Summary · context
    We have investigated the effect of different growth hormone secretagogues on contractile performance and on the susceptibility to ischemic injury, in isolated working rat hearts.
  4. 04LabEx vivo tissueEfficacy outcome

    In isolated rat hearts under aerobic conditions, MK-0677 produced no significant hemodynamic effects.

    In plain wordsIn lab tests with rat hearts, MK-0677 produced no significant changes in heart function under aerobic conditions.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAerobic hemodynamic effects
    Study

    ratn: not reported in source

    Isolated working rat hearts
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Under aerobic conditions, none of these substances produced any significant hemodynamic effects.
    2 context sentences
    Summary · context
    We have investigated the effect of different growth hormone secretagogues on contractile performance and on the susceptibility to ischemic injury, in isolated working rat hearts.
    Summary · context
    In particular, we tested the endogenous secretagogue ghrelin and the synthetic secretagogues hexarelin and MK-0677.
  5. 05LabEx vivo tissueEfficacy outcome

    In isolated rat hearts subjected to ischemia and reperfusion, MK-0677 was ineffective at reducing infarct size.

    In plain wordsIn lab tests with rat hearts, MK-0677 did not reduce infarct size after ischemia and reperfusion.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeInfarct size after ischemia and reperfusion
    Study

    ratn: not reported in source

    Isolated working rat hearts
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In hearts subjected to 30 minutes of ischemia followed by 120 minutes of reperfusion, the synthetic peptidyl secretagogue hexarelin (1 microM) significantly reduced infarct size, as estimated on the basis of triphenyltetrazolium chloride staining, while the non-peptidyl secretagogue MK-0677 was ineffective.
    2 context sentences
    Summary · context
    We have investigated the effect of different growth hormone secretagogues on contractile performance and on the susceptibility to ischemic injury, in isolated working rat hearts.
    Summary · context
    In particular, we tested the endogenous secretagogue ghrelin and the synthetic secretagogues hexarelin and MK-0677.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.